ArticlePLoS medicine2020
TIDieR-Placebo: A guide and checklist for reporting placebo and sham controls.
Article in PLoS medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 6 syntheses or guidelines pooled it.
- Can wearable real-time biofeedback gait training devices improve gait speed, balance, functional mobility and activities of daily living (ADL) in individuals post-stroke? A systematic review and meta-analysis of randomized controlled trials.Journal of neuroengineering and rehabilitation · 2025Pooled it
- Placebo setting in trials of traditional Chinese medicine nursing techniques: a systematic critical reviewBMC complementary medicine and therapies · 2025Pooled it
- Effects of Pharmacologic and Nonpharmacologic Interventions for the Management of Sleep Problems in People With Fibromyalgia: Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.Arthritis care & research · 2025Pooled it
- Effects of mind-body exercise intervention on anxiety among women: a meta-analysis.Frontiers in psychology · 2025Pooled it
- The blinding status and characteristics in acupuncture clinical trials: a systematic reviews and meta-analysis.Systematic reviews · 2024Pooled it
- Blinding, sham, and treatment effects in randomized controlled trials for back pain in 2000-2019: A review and meta-analytic approach.Clinical trials (London, England) · 2021Pooled it
- Successful Blinding or Wishful Thinking? A Secondary Analysis of a Randomised Controlled Trial of Manual Therapy.European journal of pain (London, England) · 2026Trial
- Review
- Effects of High-Velocity Elbow Manipulation on Forearm Muscle Electromyographic Recovery in Karting Drivers: A Randomized Within-Participant Sham-Controlled Trial.Journal of clinical medicine · 2026Article
- Article
- Ethical challenges of placebo use in herbal medicine trials: multiple stakeholder perspectives from qualitative interviews.BMC medical ethics · 2026Article
- Acupuncture-associated gastric mucosal repair and the EGF-EGFR-related signaling network: evidence, limitations, and prospects.Frontiers in immunology · 2026Review
- Multidimensional evaluation of four chaihu-shugan-san simulated decoction for use as placebo controls: a comparative study.Frontiers in pharmacology · 2026Article
- Unmasking three blinding indices for randomized controlled trials: comparison and application.Contemporary clinical trials communications · 2025Article
- Evaluating Manual Therapy in Musculoskeletal Pain: Why Certain Trial Designs May Overestimate Effectiveness-A Scoping Review.European journal of pain (London, England) · 2025Article
- Developing evidence-based guidelines for describing potential benefits and harms within patient information leaflets/sheets (PILs) that inform and do not cause harm (PrinciPILs).Health technology assessment (Winchester, England) · 2025Article
- Non-invasive neuromodulation for alleviating dyspnoea: protocol for a feasibility sham-controlled randomised trial.BMJ open · 2025Article
- Article
- SPIRIT 2025 explanation and elaboration: updated guideline for protocols of randomised trials.BMJ (Clinical research ed.) · 2025Article
- CONSORT 2025 explanation and elaboration: updated guideline for reporting randomised trials.BMJ (Clinical research ed.) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
backgroundPlacebo or sham controls are the standard against which the benefits and harms of many active interventions are measured. Whilst the components and the method of their delivery have been shown to affect study outcomes, placebo and sham controls are rarely reported and often not matched to those of the active comparator. This can influence how beneficial or harmful the active intervention appears to be. Without adequate descriptions of placebo or sham controls, it is difficult to interpret results about the benefits and harms of active interventions within placebo-controlled trials. To overcome this problem, we developed a checklist and guide for reporting placebo or sham interventions. METHODS AND
findingsWe developed an initial list of items for the checklist by surveying experts in placebo research (n = 14). Because of the diverse contexts in which placebo or sham treatments are used in clinical research, we consulted experts in trials of drugs, surgery, physiotherapy, acupuncture, and psychological interventions. We then used a multistage online Delphi process with 53 participants to determine which items were deemed to be essential. We next convened a group of experts and stakeholders (n = 16). Our main output was a modification of the existing Template for Intervention Description and Replication (TIDieR) checklist; this allows the key features of both active interventions and placebo or sham controls to be concisely summarised by researchers. The main differences between TIDieR-Placebo and the original TIDieR are the explicit requirement to describe the setting (i.e., features of the physical environment that go beyond geographic location), the need to report whether blinding was successful (when this was measured), and the need to present the description of placebo components alongside those of the active comparator.
conclusionsWe encourage TIDieR-Placebo to be used alongside TIDieR to assist the reporting of placebo or sham components and the trials in which they are used.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.